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Background and Objectives Umbilical cord blood (UCB) is a good stem cell
source for cell therapy. We recently demonstrated that cord blood mononuclear
cell (MNCs) subtypes were viable and functional until 96 h after collection, even
stored at room temperature. Now, we analyzed the viability and functionality of
the cells before and after cryopreservation.
Materials and Methods Twenty UCB units were analyzed at 24 and 96 h after
collection, frozen for 6 months, thawed and re-evaluated. MNCs were analyzed
by flow cytometry, viability by 7-AAD and clonogenic assays (CFU) were per-
formed.
Results After 96 h of storage, no substantial loss of MNC was found (median
7320 9 106 9 6305 9 106). Percentage and viability CD34+ cells, B-cell pre-
cursors and mesenchymal stem cells were not affected. However, mature B and T
lymphocytes as well as granulocytes had a substantial loss. CFU growth was
observed in all samples. Prefreezing storage of 96 h was associated with a rela-
tive loss of colony formation (median 12%). Postthaw, this loss had a median of
49% (24 h samples) to 56% (96 h samples).
Conclusion The delay of 96 h before UCB processing is possible, without a pro-
hibitive impairment of CD34+ loss in number and functionality.
Key words: cell therapy, cryopreservation, functionality, umbilical cord blood,
viability.
Introduction
Umbilical cord blood (UCB) is an essential therapeutic
product for hematopoietic reconstitution and expansion
and is being increasingly used for allogeneic hematopoi-
etic stem cell transplantation with good results. UCB has
also been under intense experimental investigation in
regenerative medicine. Several cord blood subpopulations
such as mesenchymal stromal cells, unrestricted somatic
stem cells and endothelial cells have been studied in dis-
tinct assays [1–11]. Moreover, cord blood cells may be
used for standardized induced pluripotent stem cell (iPSC)
generation [12].
Major advantage of using UCB for transplantation
includes the fact that the procedure may be carried out
even without total compatibility of human leucocyte anti-
gens (HLA) such as greater than or equal to 4/6 HLA (A, B,
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DRb) match. Also, two different UCB units may be infused
in the same adult patient, due to the presence of na€ıve
lymphocytes and natural killer cells, with a low incidence
of graft-versus-host disease (GVHD) maintaining the graft
vs. leukaemia effect (GVL) [13].
Cord blood processing and cryopreservation techniques
have been improved during the last two decades, increas-
ing the use of UCB volume reduction as a cost saving
alternative to diminish the cryogenic space that is very
expensive. There is an increasing demand for standardiza-
tion of procedures for collection, manipulation and cryo-
preservation to fulfil the FACT/Netcord accreditation
process [14, 15].
This quality assessment plan includes tests before
freezing and assays performed on segments attached to
the bags after thaw, to assure cord blood engraftment
after transplantation [16, 17].
Recently, many investigations comparing different
methods of CD34+ stem cell enumeration, viability evalu-
ation, and even a comparison among the different meth-
odologies have been published [18–21]. Temperature and
time of storage before freezing have been extensively
studied, but several points have remained controversial.
Most authors prefer to keep UBC units at 4°C until freez-
ing [21–23], but others, including our previous study,
have shown that UCB stem cells also remain viable and
functional if kept at 20–22°C [21, 24, 25]. Concerning
maximal time to delay for freezing, most authors have
tested the maximal time of 72 h [22, 23, 25, 26], but in
an earlier work, Pamphilon suggested that the cells could
be satisfactorily be kept until 96 h [21], which we could
confirm in our previous work [24]. All authors that ana-
lyzed samples postthaw observed that there was a larger
loss of cells after cryopreservation than after delay in
freezing, and so, they aimed to maximize the number of
cells for cryopreservation to compensate loss postthaw.
In a previous study [24] using samples already volume-
reduced for cryopreservation and stored at laboratory
room temperature (RT) (20–22°C), we demonstrated that
cord blood CD34+ stem cells while mature T lymphocytes,
immature B lymphocytes, monocytes and MSCs remained
viable up to 96 h after collection, even when stored at
RT. Only mature B lymphocytes and granulocytes
decreased significantly over time. There were no differ-
ences detected between whole blood vs. blood volume-
reduced units. We could confirm the findings of other
authors [26–29] that CD34+ stem cells maintained viabil-
ity until 72 h and were present until 96 h. Clonogenic
assays performed with samples stored fresh until 96 h
showed that functionality was also maintained for this
period [24].
Studies regarding postthaw CD34+ stem cell viability
have been also published. Xiao and Dooley [28] studied
fresh and thawed UCB MNC and have shown that the
non-viable cells in both samples were similar, revealing
2–3% of dead cells when processed 48 h after collec-
tion. Cell loss was larger in samples processed 72 h
after collection.
Brazil is the largest Latin American country having a
heavily mixed ethnic population with a great HLA diver-
sity. Brazilian Public Cord Blood Bank Network was orga-
nized in 2006. However, to cover the entire HLA
diversity, UCB units would necessarily have to be col-
lected from all geographic regions. Sometimes these units
could come from distant locations, rendering the cryo-
preservation process very difficult, as the end of proce-
dure, including collection, manipulation and freezing
should be carried out up to 48 h after collection, accord-
ing standardized by international and national regulatory
agencies.
The aim of this study was to evaluate whether CD34+
stem cells and other MNC subtypes of UCB units pro-
cessed up to 96 h after collection and submitted to cryo-
preservation could maintain good viability and
functionality after thaw.
Materials and methods
The experiments were performed with twenty UCB units
donated to the Public UCB Bank at the University of
Campinas, which did not comply with the criteria for
banking (UCB volume less than 70 ml, discounted the bag
anticoagulant volume or initial TNCs below 80 9 108),
despite fulfilling all maternal criteria (absence of family
history of genetic disorders, negative testing for viral or
bacterial infections, absence of maternal fever during
labour or delivery, gestation over 35 weeks and delivery
occurring under 24 h after rupture of membranes). All
mothers provided free informed consent before UCB unit
collection. UCB units were processed according to the
requirements of FACT/NetCord.
Umbilical cord blood collection
Collection of UCB was carried out without affecting the
delivery by a staff submitted to continuous training (e.g.
midwives and physicians). After delivery and with the
placenta still ‘in utero’, the umbilical cord was clamped
off. Thorough cleaning and disinfection was carried out
to prevent contamination with maternal blood or germs.
The umbilical vein was punctured under aseptic condi-
tions, with a 16-gauge needle and cord blood was col-
lected by gravity into a standard 250-ml collection UCB
bag (Griffols, Barcelona, Spain) containing CPD as an
anticoagulant. The procedure continued until the blood
flow stopped.
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Study design
From each collected UCB unit entering in the study,
24 ml was aspirated into a test-tube, with no volume
reduction and fractioned into two aliquots of 12 ml.
These samples were left at laboratory room temperature
(20–22°C), and immunophenotyping was made 24 and
96 h after collection (prefreezing – PF). The cells remain-
ing in the aliquots were frozen, stored for 6 months and
then thawed and reanalyzed (postthaw – PT).
Flow cytometric analysis comprised quantification of
CD34+ stem cells, mature T lymphocytes (CD4 and CD8),
mature B lymphocytes, monocytes, granulocytes, imma-
ture B-cell precursors and mesenchymal stem cells (MSCs)
was quantified. Cell viability was tested in all aliquots
(7-AAD exclusion technique).
In parallel, clonogenic assays of all samples were per-
formed for BFU-E, CFU-GM, CFU-GEMM and CFU-E.
Flow cytometry analysis
Umbilical cord blood specimens were analyzed using a
whole blood lysis technique. A six-colour combination of
monoclonal antibodies (MoAbs) was used to identify the
cell populations.
The antibodies used were purchased from BD Pharmin-
gen, San Diego, CA, USA, except for CD34 (Becton Dick-
inson – San Jose, CA, USA) and CD105 (Invitrogen –
Camarillo, CA, USA).
The combinations used at 24 and 96 h prefreezing and






The specimens were diluted to a concentration of
5 9 106/ml. Cell suspensions were incubated with the
conjugated MoAbs at room temperature in the dark for
20 min. Erythrocytes were lysed using BD Pharm Lyse
(Becton Dickinson, San Jose, CA, USA), containing no
fixative agent for 15 min in the dark at room tempera-
ture. Cells were centrifuged and the pellet was washed in
phosphate buffered saline (PBS) (Merck KGaA, Darmstadt,
Germany). The cells were resuspended in PBS until the
analysis was performed.
Data acquisition was performed on a FACSCanto II
(Becton Dickinson, CA, USA) flow cytometer using
FACSDIVA software (Becton Dickinson). At least 100 000
non-gated events were collected and analyzed, selecting
an appropriate gate on each cell population on the CD45/
SSC plot and 7-AAD to exclude non-viable cells using
the INFINICYT software (Cytognos S.L., Salamanca, Spain).
The expression of each antigen was recorded as the per-
centage from the total cell number. The strategy for
analysis is shown in Fig. 1. The same strategy of analysis
was performed on the PF and PT samples.
Clonogenic assays
Clonogenic assays were performed on samples before
freezing and immediately postthaw. Diluted UCB MNCs
(10 9 104 cells/ml), obtained by Ficoll–Hypaque (Sigma
Chemical Co., St. Louis, MO, USA) density 1077 proce-
dure, were added to 3 ml of methylcellulose medium
(Methocult GF H3343, StemCell Technologies Vancouver,
BC Canada) and 15 ml plated into two separate wells of
a six-well plate. The plates were incubated for 14 days at
37°C, in 5% CO2/95% air. CFU (BFU-E, CFU-GM, CFU-
GEMM, and CFU-E) with over fifty cells were counted
and expressed as CFUs/105 TNCs.
Freezing and thawing procedure
Samples were centrifuged for 20 min at 1880 g for plasma
reduction. An equal volume of buffy-coat and cryoprotec-
tant solution (10% dimethyl sulphoxide (DMSO); Origen
Biomedical, Austin, Texas, USA) was put into four poly-
propylene cyotubes (1 ml) through controlled-rate freezing
in the Cryo-Med cooling chamber. The cells were cooled at
1°C/min to -30°C, 5°C/min to -70°C and 10°C/min to
-90°C. Frozen cryotubes were then stored into liquid nitro-
gen containers. This procedure was performed with sam-
ples of 24 and 96 h after collection. Cells were kept frozen
up to 6 months. The thawing procedure was carried out
quickly in a water bath at 37°C and processed immediately
to perform flow cytometry analyses and clonogenic assays.
Statistical analysis
A descriptive analysis was performed for all cell subsets,
and the data were presented as the median percentages of
positive cells. The changes occurring in each cell
population throughout the observation period (24–96 h)
for prefreezing and postthaw samples were analyzed by
t-dependent test. The correlation among CFU number and
the other cell subsets was performed by Spearman corre-
lation WinStat 3.0 (Kalmia Company, Inc, Cambridge
MA, USA. The results from the clonogenic assays were
expressed as the arithmetical mean of the duplicates and
submitted to t-dependent test analyses.
Results
Considering the number of MNCs, there was a small total
mononuclear cell loss if samples were processed after
© 2014 International Society of Blood Transfusion
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Fig. 1 Flow cytometry strategy of analysis of the distribution of mononuclear cells (MNC) subsets at 24 and 96 h prefreezing (PF) and postthaw (PT),
using CD45 to separate the cell populations and 7-AAD for viability analysis at 24 and 96 h PF and PT. (a) Orange dots represent CD34+ stem cells
(CD34+C19-CD3-); immature B (CD34+CD19+CD3-) are identified as blue dots; B cells (CD34-CD19+CD3-), pink dots; and T cells (CD34+CD19-CD3+), red
dots. (b) Live cells (7-AAD-): CD34+ stem cells are identified as orange dots; immature B, blue dots; B cells, pink dots; and T cells, red dots. Dead cells
(7-AAD+): CD34+ stem cells, yellow dots; B cells, green dots; and T cells, cyan dots. (c) Monocytes (CD33+HLA-DR-CD14+), blue dots; and granulocytes
(CD33+HLA-DR-CD14-), yellow dots. (d) Live cells: monocytes, blue dots; and granulocytes, orange dots. Dead cells: monocytes, green dots; and granulo-
cytes, light blue dots. (e) MSCs (CD45-CD34-CD90+CD105+CD71+), green dots. (f) Live cells: MSCs, green dots. Dead cells: MSCs, pink dots.
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96 h instead of 24 h: median of 7320 9 106 (5120–
15700) and 6305 9 106 (3270–12100), respectively.
TNCs had a median of 49 9 108 at 24 h and 39 9 108
at 96 h. The median relative loss of TNCs for the delay of
96 h for processing was 17% (9–50).
Comparing the samples processed at 24 h and 96 h after
collection, the percentages of CD34+ stem cells increased
after 96 h of storage and did not change significantly PT
(Table 1, Fig. 2). The percentage of granulocytes decreased
after fresh storage as well as PT (Table 1, Fig. 2).
Concerning cell viability (Table 2), only the percentage of
mature T lymphocytes (especially and CD3/CD4 ones) and
granulocytes showed a significant decrease (P < 0001).
Comparing the prefreezing and postthaw samples,
granulocytes presented a significant decrease (P = 0001),
followed by mature T lymphocytes (both CD3/CD4 and
CD3/CD8) (Fig. 2). The proportion of all other subpopula-
tions remained stable postthaw after the storage period of
6 months.
The absolute number of T lymphocytes fell from a
median of 1766 to 767 9 106/ml in samples processed
at 24 h and from a median of 1954 to 1001 9 106/ml
in samples processed at 96 h. Granulocytes fell from a
median of 2445 to 740 9 106/ml in samples processed
at 24 h and from a median of 1224 to 708 9 106/ml in
samples processed at 96 h.
Concerning viability, PF and PT mature T lymphocytes
and granulocytes showed a significant loss (Table 2).
Despite of the decrease in percentage of mature B lym-
phocytes, the remaining cells viability did not decrease.
Immature B cells, monocytes and MSCs maintained a via-
bility of approximately 99%. CD34+ cells viability PF and
PT was approximately 99% (Table 2).
Clonogenic assays
The CFU growth was observed in all samples. However,
fresh samples of 96 h after collection showed a signifi-
cant decrease in colony number (P < 00001), a larger
decrease was found in samples postthaw (Fig. 3). The
median CFU number in samples stored 24 h PF was 68
(32–121) and PT was 36 (17–69). For samples processed
after 96 h, the median was 57 (31–110) and PT it was 27
(13–54).
The relative loss in CFU number in samples processed
96 h instead of 24 h after collection had a median of
12% (0–22%), demonstrated by ‘(CFU 24 h– CFU 96 h)/
CFU 24 h’. Comparing the number of colonies PT and PF,
samples processed at 24 h had a median loss of 49% (22–
57); samples processed 96 h after collection 56% (25–68).
The number of CFUs from samples processed at 24 h
had a positive correlation with the newborns’ weight
(r = 053; P = 0008 prefreezing CFUs and r = 039;
P = 004 postthaw CFUs), the number of TNCs (042;
P = 002 prefreezing CFUs and 045; P = 002 postthaw
CFUs) and a negative one with the number of non-viable
CD34+ cells prefreezing (r = -052; P = 0008 prefreezing
CFUs and r = -051; P = 0009 postthaw CFUs). For those
processed at 96 h from collection, only the relation with
TNCs was maintained (r = 049; P = 001).
Discussion
Umbilical cord blood-based therapies have been used with
considerable success, mainly for transplantation of hema-
topoietic stem cells in the treatment of blood disorders.
Recently, they have been increasingly used for novel
applications such as cellular regenerative therapy, immu-
nomodulation [30] and are also a promising stem cell
source for induced pluripotent stem cells (iPSCs) proce-
dures.
Brazilian Public Cord Blood Banks Network (Brasilcord)
was founded in 2006. Until now, (December 2013) a total
of 27538 UCB units were collected but only 17100 were
cryopreserved (rejection rate of 38%). This is keeping with
data reported from several countries all over the world
Table 1 Umbilical cord blood MNC subsets analyses in samples prefreezing and postthaw. Results were expressed as the median of the percentages
UCB MNC subtypes
Prefreezing (PF) Postthaw (PT)
24 h 96 h 24 h 96 h
CD34+ stem cells 021 (009–051) 040 (003–085) 018 (005–043) 032 (011–078)
Immature B cells 0006 (000–005) 0009 (000–009) 0003 (000–002) 0002 (000–002)
Mature B lymphocytes 543 (219–1419) 127 (045–263) 636 (191–1366) 099 (019–304)
Mature T lymphocytes 1990 (694–3977) 2710 (636–5189) 1023 (277–2740) 1487 (252–3415)
CD3/CD4 T cells 1339 (510–2713) 1872 (616–4159) 906 (326–1896) 1366 (273–3088)
CD3/CD8 T cells 661 (191–1202) 829 (165–1381) 215 (054–720) 289 (086–1108)
Monocytes 673 (201–1218) 559 (151–1050) 676 (121–1409) 543 (014–1423)
Granulocytes 3072 (1252–6288) 1850 (516–5507) 773 (083–1696) 1145 (177–3530)
MSCs 0007 (0001–002) 0008 (0001–005) 0003 (000–002) 0004 (0001–002)
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[31–33]. Only 167 units were transplanted (Brasilcord
December 2013). The optimal number of UCB that should
be banked to attend the country’s necessity is difficult to
calculate and depends on the HLA diversity of the popu-
lation and the incidence of the different diseases to be
treated. Brazil is a large country with a high HLA diver-
sity, and logistic problems may hamper the collection of
numerous units as specific HLA groups can be found in
specific remote regions.
In a previous study, we analyzed MNC cord blood cells,
including viability and functionality of CD34+ stem cells
up to 96 h after collection, stored at laboratory room
temperature (20–22°C) [24]. In the present study, we stud-
ied viability and functionality of these cells, mainly
CD34+ stem cells, after a fresh storage without volume
reduction for 96 h, cryopreservation and thawing after
6 months. This protocol better imitates a transport of UCB
from the maternity hospital to the Cord Blood Bank.







































Fig. 2 Comparison of the percentages of the several subsets of mononuclear cells at 24 and 96 h prefreezing (PF) and postthaw (PT). T Cells = mature T
lymphocytes; CD4 T Cells = T lymphocytes CD4+; CD8 T Cells = T lymphocytes CD8+; B Cells = mature B lymphocytes; GR = Granulocytes; Mono = Mono-
cytes; CD34+ = CD34+ stem cells; MSCs = Mesenchymal stem cells; Immature B Cells = Immature B lymphocytes. Significant differences were found in
T Cells, CD4 T Cells, CD8 T Cells and GR. Significant P values: 24 h PF – PT: Mature T lymphocytes (<0001), CD3/CD4 (001), CD3/CD8 (<0001), Granulocytes
(<0001). 96 h PF – PT: Mature T lymphocytes (<0001), CD3/CD4 (0005), CD3/CD8 (<0001), Granulocytes (0001) in the t-dependent test.
Table 2 Umbilical cord blood MNC subsets viability analyses at 24 and
96 h, samples prefreezing and postthaw. Results were expressed as the






24 h 96 h 24 h 96 h
CD34+ stem cells 9999 9999 9996 9996
Immature B cell 10000 10000 10000 10000
Mature B
lymphocytes
9999 9996 9953 9973
Mature T
lymphocytes
9998 9989 8647 7524
CD3/CD4 T cells 9998 9994 9118 8267
CD3/CD8 T cells 9999 9999 9715 9503
Monocytes 9997 9976 9949 9934
Granulocytes 9843 9639 8678 9497
MSCs 9999 9999 9999 9999
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We analyzed twenty samples stored at RT (20–22°C)
and processed at 24 and 96 h after collection. Prefreezing
and postthaw cell viability and functionality were ana-
lyzed and performed with whole UCB without volume
reduction.
The percentage of CD34+ stem cells maintained viabil-
ity of approximately 100%, after a delay of 96 h for pro-
cessing, similar to what was found by other authors
[26, 27]. In the present study, although the number of
colonies decreased in samples processed after 96 h,
CD34+ stem cells maintained a satisfactory viability and
functionality even stored at room temperature. There was
no significant loss of their percentage postthaw. Guttridge
et al. [25] have analyzed UCB units stored until 72 h at
RT and also demonstrated a good viability of CD34+ stem
cells. But the viability postthaw was impaired in samples
with 72 h of delay for cryopreservation. Nevertheless,
they did not examine their functionality by cell culture.
Fry et al. [22] and Radke et al. [34] also demonstrated a
good viability cells at RT or at 4°C during 72 or 48 h
after collection.
Louis et al. [23] demonstrated that viability of CD34+
stem cells and their capacity to grow in culture is not
affected when processed until 72 h after collection, simi-
larly if kept at RT or at 4°C. However, cell recovery in
NSG mice was highly decreased for samples kept at RT,
but unaffected when kept at 4°C. Yet, as it is generally
accepted that CB stem cell engraftment in patients corre-
lates well with CFU formation in vitro, the authors sug-
gest that it should be examined if this influence of
storage temperature is also observed in humans. Such a
proposal, however, is very difficult to perform under the
conditions of UCB banking, as in general, it takes a very
long time to transplant a number of UCBs banked that
would be suitable to render consistent results [35].
In our study, the colony number decreased more post-
thaw then after the delay in processing. This finding
seems a consensus among several studies [22, 34, 36, 37].
Fry et al. [22] have shown losses in CFU number mainly
after thawing. Radke et al. [34] analyzed whether the
quantity of viable CD34+ stem cells seeded affects CFU
count, and they observed a strong dependence of clono-
genic efficiency on the seeding density. They did not
observe a significant difference in cell viability between
samples of bag, aliquot and segment, but showed that
manipulation of segments is more disadvantageous for
cell viability. On the other hand, Lee et al. [36] showed
that cryopreservation time (1–5 years) does not affect
CFU number. Page et al. [38] analyzed 435 cases of CBT
confirming that the clonogenic assays (total number of
CFUs) are a strong independent predictor of neutrophil
and platelet engraftment after unrelated UCB transplanta-
tion. The same group recently described a novel scoring
system to optimize UCB unit selection for transplantation,
analyzing TNCs, MNCs, CFUs, and CD3+ and CD34+ con-
tent. Page et al. [38] results corroborated with Migliaccio
et al. and Prasad et al. All these authors demonstrated
the same range of CFU units as our study [39, 40]. So,
several features of prefreezing, freezing and storage con-
ditions may affect the stem cell competence of engraft-
ment in vivo, and results of several studies are hard to
compare.
The proportion of mature B lymphocytes decreased
during the period prefreezing but not postthaw. Kessel
et al. [41] have shown that cord blood B cells present a
higher apoptotic rate when compared to peripheral adult
Fig. 3 Distribution CFU number of samples
stored at room temperature at 24 and 96 h PF
and PT. An important decrease was observed
postthaw when compared with prefreezing
samples.
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B cells. These cells have a lower expression of Bcl-2 that
plays a pivotal role in modulating membrane integrity
and the release of apoptogenic factors from mitochondria.
Cord blood B cells also show a low bcl-2/bax ratio. Leco-
eur et al. [42] have shown that living CD19+ B lympho-
cytes may have a low expression of this antigen, and
consequently, apoptotic B-cells phenotyping could be
misleading. CD19+ B cells high sensibility to temperature
variations, demonstrated by Paxton and Bendele [43],
could be another hypothesis. B-cell precursors maintained
similar proportions as found in our previous study.
Mesenchymal stem cells maintained almost the same
percentages as in the prefreezing samples, showed a ten-
dency to decrease postthaw maintaining their viability.
Moreover, MSCs must necessarily be analyzed to verify
whether they would be able to maintain their great
capacity of proliferation and differentiation into other cell
lineages.
Taken together, we can conclude that delay in process-
ing UCB causes a small decrease of TNCs, but the cell loss
was more pronounced postthaw. The proportion and via-
bility of CD34+ stem cells was maintained although col-
ony formation decreased, especially postthaw. The
number of colonies obtained postthaw in samples pro-
cessed 24 h after collection could be predicted by the
newborn’s weight, TNCs and the non-viable percentage of
CD34+ stem cells prefreezing. No quality control per-
formed by flow cytometry postthaw could predict this
number. There was also a substantial change in the pro-
portions of B and T lymphocytes as well as of granulo-
cytes. How this could affect the immunological recovery
after transplantation, the incidence of GVHD and relapses
remains to be examined [44–46].
Concerning samples processed after 96 h, besides the
number of TNCs prefreezing no other variables showed a
relation with the number of CFUs postthaw, which could
be considered as a gold standard of functionality of the
UCB for cell therapy.
These data indicate that UCB could be processed up to
4 days from collection, which would increase the number
of units collected with specific HLA phenotype, even in
distant regions.
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